Aurinia Pharmaceuticals
AUPH
166 hedge funds and large institutions have $965M invested in Aurinia Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 44 increasing their positions, 50 reducing their positions, and 35 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
51% more capital invested
Capital invested by funds: $641M → $965M (+$324M)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
7% more call options, than puts
Call options by funds: $118M | Put options by funds: $111M
1% less funds holding
Funds holding: 167 → 166 (-1)
4.46% less ownership
Funds ownership: 38.55% → 34.09% (-4.5%)
12% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$48.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.9M |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$12.7M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$9.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$78.7M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$20.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$9.51M |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$7.25M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$6.51M |
AUPH Hedge Fund Activity: Q3 2021 in Review
166 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2021, worth a combined $965M — up 51% from $641M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AUPH positions and 35 closed out — a net gain of 3 holders — while 44 added to existing stakes and 50 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $48.9M. The largest seller was OrbiMed, exiting entirely with an estimated $78.7M sold.
- 166 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2021, down from 167 in Q2 2021.
- Funds reported $965M of Aurinia Pharmaceuticals stock for Q3 2021, up 51% quarter-over-quarter.
- 38 funds opened new Aurinia Pharmaceuticals positions in Q3 2021 and 35 closed out, a net change of +3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2021 was Morgan Stanley, an estimated $48.9M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2021 was OrbiMed, an estimated $78.7M sold.
Based on aggregated 13F filings for Q3 2021.